|
|
|
|
|
|
Sponsors and Collaborators: |
University of Oslo Laerdal Medical Ullevaal University Hospital Health Region East, Norway Norwegian Air Ambulance |
Information provided by: | University of Oslo |
ClinicalTrials.gov Identifier: | NCT00121524 |
Intravenous epinephrine has been part of the guidelines for cardiopulmonary resuscitation since the start. It improves outcome in animal studies, but has never been investigated in a controlled study in humans. Epidemiologic data indicate that it is an independent negative predictor for survival. If this is true in a controlled randomized study, it could be due to effects of the drug itself or more likely due to reduced quality of chest compressions and ventilations due to the time spent on placing an I.V. needle and injecting drugs.
Condition | Intervention | Phase |
Cardiac Arrest |
Drug: epinephrine and intravenous needle |
Phase II |
MedlinePlus related topics: | CPR |
Drug Information available for: | Epinephrine Epinephrine bitartrate Amiodarone Amidox Amiodarone hydrochloride |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Effects of Epinephrine and I.V. Needle on CPR Outcome |
Enrollment: | 904 |
Study Start Date: | January 2003 |
Study Completion Date: | June 2008 |
Primary Completion Date: | May 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
IV yes: Experimental
ACLS with an iv needle and the use of drugs during CPR
|
Drug: epinephrine and intravenous needle
epinephrine 1 mg iv. q 3 min during CPR, atropin 3 mg iv in initial asystole, amiodarone 300 mg iv after repeated failed defibrillation attempts
|
IV no: No Intervention
No IV needle or drugs given during CPR
|
Drug: epinephrine and intravenous needle
epinephrine 1 mg iv. q 3 min during CPR, atropin 3 mg iv in initial asystole, amiodarone 300 mg iv after repeated failed defibrillation attempts
|
In a randomized, controlled study of all out-of-hospital cardiac arrest patients in Oslo, Norway, half the patients are treated according to the international guidelines for advanced CPR, and the other half according to the same guidelines, except for no I.V. needle or drugs are given until 5 minutes after eventual return of spontaneous circulation.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Norway | |||||
Ulleval University Hospital | |||||
Oslo, Norway, N-0407 |
University of Oslo |
Laerdal Medical |
Ullevaal University Hospital |
Health Region East, Norway |
Norwegian Air Ambulance |
Principal Investigator: | Lars Wik, MD, PhD | Ullevaal University Hospital |
Responsible Party: | University of Oslo and Ulleval University Hospital ( Petter Andreas Steen/professor ) |
Study ID Numbers: | 525-02201 |
First Received: | July 13, 2005 |
Last Updated: | June 11, 2008 |
ClinicalTrials.gov Identifier: | NCT00121524 |
Health Authority: | Norway: The National Committees for Research Ethics in Norway |
|
|
|
|